Do non-steroidal anti-inflammatory drugs increase or decrease cardiovascular risk in patients with rheumatoid arthritis?

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages 8-9

  Sfikakis, Petros P ^a   Bournia, V K ^a   Kitas, G ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; LETTER; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; PROTECTION; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; PROTECTIVE FACTORS; RISK FACTORS;

EID: 84922552491     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. HIPPISLEY-COX J, COUPLAND C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
2. CHAN AT, MANSON JE, ALBERT CM et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113: 1578-87.
3. BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
4. STAMATELOPOULOS KS, KITAS GD, PAPA-MICHAEL CM et al.: Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009; 29: 1702-8.
5. PETERS MJL, VAN HALM VP, VOSKUYL AE et al.: Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61: 1571-9.
6. PROTOGEROU AD, PANAGIOTAKOS DB, ZAMPELI E et al.: Arterial hypertension assessed "out-of-office" in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated "white coat" phenomenon. Arthritis Res Ther 2013; 15: R142.
7. ROBERTSON J, PETERS MJ, McINNES IB, SATTAR N: Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013; 9: 513-23.
8. PETERS MJ, SYMMONS DP, McCAREY D et al.: EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
9. GOODSON NJ, BROOKHART AM, SYMMONS DP, SILMAN AJ, SOLOMON DH: Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009; 68: 367-72.
10. FERRAZ-AMARO I, MACHIN S, CARMONA L, GONZALEZ-ALVARO I, DIAZ-GONZALEZ F: Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice. Reumatol Clin 2009; 5: 252-8.
11. LINDHARDSEN J, GISLASON GH, JACOBSEN S et al.: Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2013 Jun 8 [Epub ahead of print].
12. GARNER SE, FIDAN D, FRANKISH RR et al.: Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005; 25: CD003685
13. COLEBATCH AN, MARKS JL, van der HEIJDE DM, EDWARDS CJ: Safety of non-steroidal anti-inflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012; 90: 62-73.
14. MARKS JL, van der HEIJDE DM, COLEBATCH AN, BUCHBINDER R, EDWARDS CJ: Pain pharmacotherapy in patients with inflammatory arthritis and concurrent cardiovascular or renal disease: a Cochrane systematic review. J Rheumatol Suppl. 2012; 90: 81-4.
15. VAN BREUKELEN van-der STOEP DF, KLOP B, VAN ZEBEN D, HAZES JMW, CABEZAS MC: Cardiovascular risk in rheumatoid arthritis: How to lower the risk? Atherosclerosis 2013; 231: 163-72.